• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    EVP, Pres of ED, CMO & CSO Caveney Brian J was granted 4,840 shares and covered exercise/tax liability with 2,109 shares, increasing direct ownership by 9% to 32,067 units (SEC Form 4)

    3/31/25 10:24:03 AM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Caveney Brian J

    (Last) (First) (Middle)
    531 SOUTH SPRING STREET

    (Street)
    BURLINGTON NC 27215

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LABCORP HOLDINGS INC. [ LH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, Pres of ED, CMO & CSO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/27/2025 A(1) 4,840 A $0 34,175.6573 D
    Common Stock 03/27/2025 F(2) 2,109 D $231.67 32,066.6573 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares acquired on March 27, 2025, pursuant to a performance award granted on February 11, 2022, relating to performance during the three-year period ended December 31, 2024.
    2. Stock withholding to satisfy tax withholding obligations.
    /s/ Sandra D. van der Vaart, Attorney-in-Fact for Brian J. Caveney 03/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    2/26/2024$260.00Outperform
    Leerink Partners
    More analyst ratings

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces 2025 First Quarter Results

      Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:Revenue guidance of 6.7% to 8.0%Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05Free Cash Flow of $1.10 billion to $1.25 billionProviding broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-dateIntroduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid

      4/29/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

      Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C., April 23, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by th

      4/23/25 7:00:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2025, to stockholders of record as of the close of business on May 29, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confid

      4/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

      Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

      4/2/25 8:50:29 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Citigroup with a new price target

      Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

      3/4/25 7:36:42 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Labcorp Holdings Inc. from In-line to Outperform and set a new price target of $265.00 from $260.00 previously

      1/7/25 8:12:52 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    SEC Filings

    See more
    • SEC Form 144 filed by Labcorp Holdings Inc.

      144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

      5/1/25 11:07:09 AM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Labcorp Holdings Inc.

      10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)

      4/29/25 11:34:58 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

      4/29/25 6:53:52 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    See more
    • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

      Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

      11/19/24 7:00:00 AM ET
      $BGNE
      $LH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Advantage Healthcare Holdings Appoints Dinak Nair as Chief Executive Officer

      Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served

      9/25/24 11:19:00 AM ET
      $AHCO
      $LH
      Medical/Nursing Services
      Health Care
      Medical Specialities

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Legal Officer Van Der Vaart Sandra D sold $452,884 worth of shares (1,900 units at $238.36), decreasing direct ownership by 46% to 2,244 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      5/5/25 12:45:59 PM ET
      $LH
      Medical Specialities
      Health Care
    • SVP, Chief Accounting Officer Wilkinson Peter J sold $200,838 worth of shares (829 units at $242.26), decreasing direct ownership by 29% to 2,054 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      5/5/25 12:45:10 PM ET
      $LH
      Medical Specialities
      Health Care
    • EVP, Pres, Central Labs & Intl Bailey Megan D. converted options into 4,287 shares and covered exercise/tax liability with 1,614 shares, increasing direct ownership by 366% to 3,403 units (SEC Form 4)

      4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

      4/3/25 8:47:04 AM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Financials

    Live finance-specific insights

    See more
    • Labcorp Announces 2025 First Quarter Results

      Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:Revenue guidance of 6.7% to 8.0%Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05Free Cash Flow of $1.10 billion to $1.25 billionProviding broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-dateIntroduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid

      4/29/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp Declares Quarterly Dividend

      BURLINGTON, N.C., April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2025, to stockholders of record as of the close of business on May 29, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confid

      4/10/25 6:50:00 AM ET
      $LH
      Medical Specialities
      Health Care
    • Labcorp to Announce First Quarter Financial Results on April 29, 2025

      BURLINGTON, N.C., March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

      3/31/25 4:15:00 PM ET
      $LH
      Medical Specialities
      Health Care

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

      SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

      2/13/24 5:08:06 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

      SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

      7/24/23 4:20:26 PM ET
      $LH
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

      2/10/21 11:14:27 AM ET
      $LH
      Medical Specialities
      Health Care